| |
Asilomar Pharmaceuticals has staked an early claim to receptor-mediated drug delivery to the peripheral nervous system (PNS). This company is combining its proprietary "linker" chemistry technology with off-patent (generic) pharma-ceuticals to treat PNS-related disorders, like shingles, neuropathic pain, diabetic neuropathy, and herpes. There are only marginally effective treatments or none at all for these very large markets. Asilomar has patented a "linker" chemistry which when conjugated with a generic drug, the resulting conjugate is transported from the end of a nerve up along its length, avoiding the blood-brain barrier, and bringing the active drug to the neuronal cells along the neural pathway. TASCF invested alongside Sears Capital, Asset Management, SBV Ventures and several angel investors in the first round. |
|
